ArticleEClinicalMedicine2023

Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials.

Zhishan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.